News & Updates

Patients who receive sacubitril-valsartan after an acute myocardial infarction (MI) have a similar health status, as determined by EQ-5D visual analog scale (VAS) score, compared with those who receive ramipril, according to results of a prespecified analysis of the PARADISE-MI trial presented at HFSA 2021.

Survivors of bacterial meningitis (BM) suffer from an impaired health-related quality of life (HRQOL), regardless of possible disability, a study using parents’ perceptions has concluded.

Treatment with corticosteroids (CS) among children with multisystem inflammatory syndrome (MIS-C) cardiovascular involvement temporarily associated with COVID-19 leads to faster normalization of left ventricular ejection fraction (LVEF), fever, improved laboratory analysis, and shorter intensive care unit stay than treatment with intravenous immunoglobulin (IVIG), a study has shown.

Maintenance treatment with bimekizumab achieves complete scalp, palmoplantar, or nail clearance in patients with moderate-to-severe plaque psoriasis, according to two phase III trials presented at EADV 2021.

The oral selective Janus kinase 1/2 inhibitor baricitinib, when added to standard of care (SoC), reduced the risk of mortality among adults hospitalized with COVID-19. However, the primary outcome of disease progression was not met in the baricitinib group, results of the phase III COV-BARRIER study showed.